Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept.

@article{Varnavas2004AnthranilicAB,
  title={Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept.},
  author={A. Varnavas and L. Lassiani and V. Valenta and F. Berti and A. Tontini and L. Mennuni and F. Makovec},
  journal={European journal of medicinal chemistry},
  year={2004},
  volume={39 1},
  pages={
          85-97
        }
}
Recently we described an innovative class of non-peptide CCK(1) antagonists keeping appropriate pharmacophoric groups on the anthranilic acid employed as a molecular scaffold. The lead compound obtained, VL-0395, characterized by the presence of Phe and the 2-indole moiety at the C- and N-termini of anthranilic acid, respectively, is endowed with submicromolar affinity towards CCK(1) receptors. Thus, we have prepared and tested on CCK receptors a library of VL-0395 analogues in order to… Expand
Anthranilic acid based CCK1 receptor antagonists: preliminary investigation on their second "touch point".
TLDR
The result of this work is the identification of a new CCK ligand, which possesses an affinity one order of magnitude greater than the lead and points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Expand
Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand.
TLDR
It is demonstrated that the CCK(1) receptor affinity depends on the nature of the aminoacidic side chain as well as that the free carboxy group of the alpha-aminoacids is crucial for the binding. Expand
New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R).
TLDR
New compounds provided by this study represent a solid basis for further advances aimed at synthesis of clinically valuable CCK(1)-R antagonists. Expand
Twenty years of non-peptide CCK1 receptor antagonists: all that glitters is not gold
During the last 20 years, pharmaceutical industry and academic efforts have led to several structurally unrelated classes of non-peptide cholecystokinin-1 receptor (CCK1-R) antagonists. Due to theExpand
2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'.
TLDR
From the GRIND models it can be deduced that the shape differences of the molecules are secondary in the regulation of the activity, or better, that their polar substituents are capable of occupying the same zones of the space in the most of the cases. Expand
Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity.
TLDR
Evaluation of the CCK(1) SAR in a series of these diarylpyrazole antagonists was conducted in a matrix synthesis format revealing additive (Free-Wilson) and non-additive SAR. Expand
Tetrahydro anthranilic acid as a surrogate for anthranilic acid: application to the discovery of potent niacin receptor agonists.
The design, synthesis, and biological activity of a series of cycloalkene acid-based niacin receptor agonists are described. This led to the discovery that tetrahydro anthranilic acid is an excellentExpand
Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors.
TLDR
This report reports on the structure-activity relationship of a series of hydroxamate BoNT/A inhibitors, which displayed comparable inhibitory activity to that of the lead structure. Expand
Synthesis of the 1-monoester of 2-ketoalkanedioic acids, for example, octyl α-ketoglutarate.
  • M. Jung, G. Deng
  • Chemistry, Medicine
  • The Journal of organic chemistry
  • 2012
TLDR
Oxidative cleavage of cycloalkene-1-carboxylates, made from the corresponding carboxylic acids, and subsequent oxidation of the resulting ketoaldehyde afforded the important 1-monoesters of 2-ketoalkanedioic acids, a cell-permeable prodrug form of α-ketoglutarate and a promising therapeutic agent in its own right. Expand
The synthesis and conformational analysis of amino acid-tetrahydroanthranilic acid hybrids
Abstract The optimization of a palladium-catalyzed amidation reaction providing a new class of amino acid–tetrahydroanthranilic acid derivatives has been achieved. The scope of the reaction andExpand
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
Anthranilic acid derivatives: a new class of non-peptide CCK1 receptor antagonists.
TLDR
On the basis of the main pharmacophoric groups of the obtained new lead compound (1) (coded VL-0395) a receptor binding hypothesis has been provided and simplified analogues reducing the anthranilic acid dimer to a monomer are proposed. Expand
Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactams.
A series of 1,3-substituted benzolactams are reported that are potent nonpeptidal antagonists of the peptide hormone cholecystokinin (CCK). Design considerations were based upon the natural productExpand
Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718.
TLDR
A series of novel nonpeptide cholecystokinin-A (CCK-A) antagonists have been synthesized on the basis of the structural homology between lorglumide and L-364,718 to constitute a link between the N-acylglutamic acid and 3-amino-5-phenyl-1,4-benzodiazepin-2-one derived antagonists. Expand
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives.
TLDR
The characteristics of CR 2194, that is, the selectivity for the gastrin receptor, the simple nonpeptidic molecular structure, and the activity after oral administration, indicate that this compound is a useful tool in the study of the biological effects of gastrin and a potential agent for diagnostic or therapeutic use. Expand
Novel glutamic acid derived cholecystokinin receptor ligands.
TLDR
Novel aryl amide analogues of glutamic acid dialkylamide have been synthesized to test for a possible structural analogy between glutamic Acid and benzodiazepine CCK antagonists and appear to be most useful in the design of selective ligands for the pancreas type CCK receptor. Expand
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.
TLDR
3-(Acylamino)-5-phenyl-2H-1,4-benzodiazepines, antagonists of the peptide hormone cholecystokinin (CCK), are described, and the method of development of these compounds is discussed in terms of its relevance to the general problem of drug discovery. Expand
Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK-480. Synthesis and structure-activity relationships of FK-480 and related compounds.
TLDR
FK-480, a novel tricyclic 1,4-benzodiazepine derivatives as cholecystokinin (CCK) A antagonists, is now undergoing clinical studies for the treatment of chronic pancreatitis. Expand
Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines.
TLDR
In vivo activity of selected compounds in mice is presented and the structure/activity profile of this class of benzodiazepines as CCK antagonists is discussed, and all compounds proved to have greater affinity for the peripheral CCK receptor. Expand
Benzimidazole‐type Glycine Antagonists: The Role of the Ring Nitrogen Atoms
TLDR
N‐Methylation strongly reduced the potencies of both BICA and ICA derivatives, indicating that also a nitrogen atom lacking a hydrogen atom can be engaged in glycine receptor interaction. Expand
Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
TLDR
In summary, SR 27897 is a selective antagonist of CCKA receptors, is highly potent in animal models whatever the route of administration and has a long duration of action. Expand
...
1
2
3
...